Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
To evaluate the potential usefulness of 18F-AIPF-1026 positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-A-related disease patients.
ClinicalTrials.gov IDNCT07685860
PhaseNot Applicable
Enrollment200
SponsorTianjin Medical University
Age18 Years
SexALL
Conditions studied
Depression, Anxiety, Heart Injuries
About this study
To evaluate the potential usefulness of 18F-AIPF-1026 positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-A-related disease patients.
Interventions
- Diagnostic Test: Diagnostic Test: 18F-AIPFA-1026 — Each subject receive a single intravenous injection of 18F-AIPF-1026, and undergo PET/ CT or MRI imaging within the specificed time.
Primary outcomes
- Standardized uptake value (SUV) (30 days)
Eligibility information
Inclusion Criteria:
\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated depression (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled MAO-A PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Study locations
- The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230000 China
- The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000 China
- Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality 300052 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.